Changchun High-Tech Industry (000661.SZ): GenSci's application for registering clinical trials for the production of 145 domestically produced drugs has been approved.

16:16 23/01/2026

Changchun High-tech (000661.SZ) announcement, the company's subsidiary - Changchun GenSci Pharmaceutical Co., Ltd. (referred to as "GenSci Pharmaceuticals") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The domestic production drug registration clinical trial application for GenSci 145 tablets has been approved. GenSci 145 tablets is a new type of mutated selective PI3K inhibitor developed by GenSci Pharmaceuticals, which is classified as a first-class innovative chemical drug and is intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations.

Changchun High-Tech Industry (000661.SZ) announcement, the company's subsidiary - Changchun JinSai Pharmaceutical Co., Ltd. (referred to as "JinSai Pharmaceutical") has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. JinSai Pharmaceutical's domestic production drug GenSci145 tablets registration clinical trial application has been approved. GenSci145 tablets is a new type of selective PI3K inhibitor developed by JinSai Pharmaceutical, belonging to Class 1 innovative chemical drugs, intended for the treatment of locally advanced or metastatic solid tumors carrying PIK3CA mutations.

ASIA CEMENT CH (00743) Announces Profit Increase, Expected Net Profit Attributable to Equity Holders for 2025 to be Approximately 85.6 Million Yuan, Turnaround from Loss to Profit compared to previous year.

XUANWU CLOUD (02392) spent HKD 14,200 to repurchase 10,000 shares on January 23rd.

China Aluminum International Engineering Corporation (02068) and its subsidiary Shenyang Institute, together with Shanghai Baoye and China 12th Metallurgical Group, have signed a "Construction Project Engineering General Contract (Joint Venture)" with Shanxi Zhaofeng.

XUANWU CLOUD (02392) spent HKD 14,200 to repurchase 10,000 shares on January 23rd.